Flutter®
DeviceAcute exercise with Flutter® breathing therapy.
NCT Number: NCT02750722
The investigators aim to compare a single bout of moderately intense cycling exercise incorporating Flutter® breathing maneuvers with a single bout of moderately intense cycling exercise alone on sputum viscoelasticity (primary endpoint) and the diffusion capacity of the lungs in adult patients with cystic fibrosis.
The investigators further aim to analyze the short-term variability of resting diffusion capacity of carbon monoxide (DLCO) and nitric oxide (DLNO) in patients with cystic fibrosis.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
ETH Zurich, Zurich, Canton of Zurich, Switzerland
Regular airway clearance is an integral component of cystic fibrosis care and of critical importance to lung health. Exercise and standardized chest physiotherapy are accepted airway clearance techniques in cystic fibrosis. Different airway clearance techniques are available, but there is no evidence that one technique or a combination is superior. Oscillatory positive expiratory pressure with the Flutter® is a widely used airway clearance technique in the European countries and has been shown to favourably alter sputum viscoelasticity in cystic fibrosis.
This randomized crossover study is designed to assess the acute effects of combined cycling exercise and Flutter® therapy on sputum viscoelasticity (primary outcome measure) and gas diffusion in adults with cystic fibrosis.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Acute exercise with Flutter® breathing therapy.
Acute exercise without Flutter® breathing therapy.
Time frame: Baseline - immediately post exercise - 45min post exercise
Sputum viscoelasticity measured by stress/strain controlled rheometer (Anton Paar, MCR 301/MCR 501).
Time frame: Baseline - immediately post exercise - 45min post exercise
Shear viscosity measured by stress/strain controlled rheometer (Anton Paar, MCR 301/MCR 501).
Time frame: Baseline - immediately post exercise - 45min post exercise
Measured with a Capillary Breakup Extensional Rheometer (CaBER).
Time frame: Baseline - immediately post exercise - 45min post exercise
Sputum weight of a 50 μL aliquot before and after lyophilization to dryness using a freeze dryer.
Time frame: Baseline - immediately post exercise - 45min post exercise
Single-breath measurements with MasterScreenTM PFT system
Time frame: Baseline - immediately post exercise - 45min post exercise
Single-breath measurements with MasterScreenTM PFT system
Time frame: Baseline - immediately post exercise - 45min post exercise
Single-breath measurements with MasterScreenTM PFT system
Time frame: Baseline - immediately post exercise - 45min post exercise
Single-breath measurements with MasterScreenTM PFT system
Time frame: Baseline - immediately post exercise - 45min post exercise
Single-breath measurements with MasterScreenTM PFT system
Time frame: Baseline - immediately post exercise - 45min post exercise
Single-breath measurements with MasterScreenTM PFT system
Time frame: Baseline - immediately post exercise - 45min post exercise
Assessed by a visual analogue scale (0-10)
Time frame: Baseline - immediately post exercise - 45min post exercise
Measured by pulse oximetry.
University of Zurich
Other
Acute Effects of Combined Exercise and Oscillatory Positive Expiratory Pressure Therapy on Sputum Properties and Lung Diffusion Capacity in Cystic Fibrosis: a Randomized Crossover Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02821130
Behavior, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Vancouver, British Columbia, Canada
View Trial DetailsNCT01799642
Behavior, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Vancouver, British Columbia, Canada
View Trial DetailsNCT05279040
Behavior, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Vancouver, British Columbia, Canada
View Trial DetailsNCT02700243
Behavior, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
View Trial Details